Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: TRI

ExeGi Pharma Announces First Patient Enrollment in the PROF Trial of EXE-346

ROCKVILLE, Md., Dec. 8, 2023 /PRNewswire/ -- ExeGi Pharma, a pioneering biopharmaceutical company dedicated to the development and commercialization of innovative live biotherapeutics, has announced the first patient enrollment in its landmark PROF Trial. The trial will study the potential of EXE-346, a novel live biotherapeutic, as treatment for excessive stool frequency in patients with an ileal pouch-anal anastomosis. Live biotherapeutics are similar to probiotics in that they contain live beneficial bacteria, however live biotherapeutics as therapeutic drug products require FDA approval.

Ileal pouch-anal anastomosis (IPAA) is a surgical procedure often employed for patients with ulcerative colitis which results in a significantly altered gastrointestinal tract. A subset of these patients experience chronic excessive stool frequency, which severely impacts their quality of life. EXE-346 aims to offer hope and a potential solution to this issue.

Dr. Hans Herfarth, the principal investigator for the PROF Trial and Director of the University of North Carolina Multidisciplinary IBD Center commented, "We are optimistic about the potential of EXE-346. This trial represents a significant step forward in our commitment to improving outcomes and advancing the standard of care for patients suffering from complications associated with ileal pouch-anal anastomosis."

The PROF Trial is anticipated to provide valuable insights into the therapeutic application of EXE-346 in IPAA patients with debilitating stool frequency challenges.

"We are excited to embark on this pivotal trial, and the enrollment of our first patient is a monumental milestone," said Marc Tewey, CEO of ExeGi Pharma. "We remain deeply committed to developing groundbreaking solutions and hope that EXE-346 will pave the way for a new era in the management of ileal pouch disorders."

The PROF Trial will continue patient recruitment across multiple sites, aiming for robust and comprehensive results that will guide future applications of EXE-346.

For more information on the PROF Trial, please refer to the clinicaltrials.gov posting (NCT05938465) or visit www.profclinicalstudy.com.

About ExeGi Pharma

ExeGi Pharma LLC is a biotechnology company focused on the development and commercialization of live biotherapeutic and probiotic medicines. ExeGi's team leverages scientific expertise in the field of microbiome science to deliver novel, clinically supported live biotherapeutic and probiotic products for a variety of unmet health and medical needs. ExeGi is headquartered in Rockville, Md.

SOURCE ExeGi Pharma

These press releases may also interest you

at 05:15
The "Global Continuing Medical Education Market - Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering. The global continuing medical education market is expected to reach a value of $13.52 billion by 2028 from...

at 05:00
The "Wilms Tumor Protein Global Market Report 2024" has been added to ResearchAndMarkets.com's offering. The Wilms Tumor Protein market size is expected to see strong growth in the next few years. It will grow to $4.06 billion in 2028 at a compound...

at 05:00
Freegold Ventures Limited is pleased to report drill results from the Saddle Zone drilling as part of the 2023 exploration program at Golden Summit. The 2023 program has been very successful in demonstrating significant expansion potential with...

at 03:45
PCs will be the main driver of growth in the AI edge processor market over the next four years, according to new research from Omdia. This was among the results announced by Omdia in the 2023 edition of its AI Processors for the Edge Forecast, which...

at 03:01
SolarBank Corporation (Cboe CA: SUNN) ("SolarBank" or the "Company") reports second quarter 2024 interim financial results. All financial figures are in Canadian dollars and in accordance with International...

at 02:00
Centamin will announce its audited financial results for the twelve months ended 31 December 2023 on Thursday, 21 March 2024.The Company will host a webcast presentation on the same day, at 08.30 GMT, to discuss the results with investors and...

News published on and distributed by: